Figure 6.
A summary diagram outlining the regulatory network of SOS1 in CML
Targeting the inhibition SOS1 using siRNA arrested the cell cycle by depressing the PI3K-AKT signal pathway and increased drug sensitivity or overcame drug-resistance by promoting the expression of SLC22A4. BAY-293 is an inhibitor of SOS1, which blocks Ras activation and improves imatinib response through the expression of SLC22A4.